Epitome Therapeutics
Develops biotechnology therapeutics programmes, using pre-seed capital to advance its pipeline and expand its team.
Overview
Epitome Therapeutics is an Austrian biotechnology startup developing therapeutic programmes. The provided funding announcement does not disclose its modalities, disease areas or use of AI, so the company is best characterized as a deep-tech drug development venture rather than an AI infrastructure or software business. The company raised €4 million in pre-seed funding, reported as $4 million total raised, to advance its programmes and grow its team. Its target market is the therapeutics and biopharma sector, with differentiation tied to its internal pipeline as further details emerge.
Funding History
Austrian BioTech startup Epitome Therapeutics announces €4 million in funding to advance programmes and grow team
Frequently Asked Questions
- How much has Epitome Therapeutics raised in total?
- Epitome Therapeutics has raised a total of $4M across 1 funding round.
- Who are Epitome Therapeutics's investors?
- Epitome Therapeutics's investors include Undisclosed.
- What does Epitome Therapeutics do?
- Epitome Therapeutics is an Austrian biotechnology startup developing therapeutic programmes. The provided funding announcement does not disclose its modalities, disease areas or use of AI, so the company is best characterized as a deep-tech drug development venture rather than an AI infrastructure or software business. The company raised €4 million in pre-seed funding, reported as $4 million total raised, to advance its programmes and grow its team. Its target market is the therapeutics and biopharma sector, with differentiation tied to its internal pipeline as further details emerge.
- Where is Epitome Therapeutics headquartered?
- Epitome Therapeutics is headquartered in San Francisco, CA.
Investors
Related Insights
A comprehensive analysis of Isembard's funding history, investors, competitive position, and growth trajectory in the Deep Tech space.
Compare the leading AI-focused VC firms: Andreessen Horowitz, Sequoia Capital, Thrive Capital, and 7 more. Analysis of 150+ AI deals, investment strategies, sector focus, and portfolio performance.
395 AI funding deals worth $337B tracked in 2026. Complete guide to raising pre-seed, seed, Series A/B/C+ for AI startups. Valuations, metrics VCs demand, top investors (Sequoia, a16z, Lightspeed), and how AI funding differs from traditional tech. Includes real deal sizes, timelines, and founder strategies.